profit from every SEK 100 of sales.
SEK 0SEK 100
MedCap
SEK 555.50+1.09% today
+7.4% in 1 year
1-year low SEK 453.001-year high SEK 600.50
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 37.85 for every SEK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What MedCap sold, what it kept, and what it did with the cash.
Sales went from SEK 1.11 billion in 2022 to SEK 2.11 billion in 2025, with SEK 220 million of profit last year.
SalesProfit
MedCap handed back 9% of the cash it generated last year.
Buybacks SEK 26M
Free cash flow 2025SEK 281M
Bought back its own sharesSEK 26M
Paid as dividends–
Cash vs. debtSEK 370M vs. SEK 483M
MedCap vs. similar companies
MedCap grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| MedCap | 37.8× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads MedCap's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,111 | 1,587 | 1,807 | 2,108 | |
| 677 | 927 | 1,057 | 1,236 | |
| 149 | 215 | 241 | 289 | |
| 256 | 342 | 396 | 474 | |
| 118 | 172 | 207 | 220 | |
| 7.90 | 11.60 | 14.00 | 14.70 | |
| 60.9% | 58.4% | 58.5% | 58.6% | |
| 13.4% | 13.6% | 13.3% | 13.7% | |
| 10.6% | 10.8% | 11.5% | 10.4% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,429 | 1,662 | 1,991 | 2,606 |
| Cash | 236 | 188 | 370 | 370 |
| Total debt | 340 | 261 | 358 | 483 |
| Total liabilities | 571 | 635 | 703 | 1,147 |
| 856 | 1,023 | 1,282 | 1,452 | |
| 15 | 15 | 15 | 15 | |
| 11.2% | 14.7% | 13.6% | 13.2% | |
| 13.7% | 16.8% | 16.2% | 15.1% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 86 | 228 | 360 | 343 | |
| 44 | 39 | 66 | 62 | |
| 41 | 189 | 294 | 281 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 26 | |
| – | – | – | – |
Valuation
- 37.8×
- –
- 1.65
- 5.1×
- 3.9×
- 29.7×
- 17.8×
- 3.4%
- 2.6%
- –
Profitability
- 58.6%
- 13.7%
- 10.4%
- –
- 13.2%
- 13.1%
- –
- –
- –
- –
Growth
- +23.8%
- +23.0%
- –
- –
- +0.4%
Financial health
- 0.2×
- 0.33
- –
- 10.2×
- 2.00
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 18%of 963
Top 41%of 894
Bottom 34%of 632
Top 23%of 908
Top 34%of 991
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
60Pass
Benjamin Graham
40No pass
Philip Fisher
67Pass
Peter Lynch
71Pass
Joel Greenblatt
17No pass
Charlie Munger
54No pass
Terry Smith
56No pass
Questions about MedCap
Is MedCap a good stock to buy?
A solid business, but the price is high. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MedCap AI analysis
What does MedCap do?
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It is in Medical Devices, based in Stockholm, Sweden, with 637 employees.
Is MedCap stock halal?
Yes. MedCap passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has MedCap stock done over the past year?
Up 7.4% over the past twelve months, to SEK 555.50. It traded between SEK 453.00 and SEK 600.50 and is 7.5% below its high.
Who are MedCap's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with MedCap's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.